I'd like to bring to your attention an international campaign to have all clinical trials registered with the full data sets disclosed for assessment in licensing and so on. The campaign is called 'AllTrials' and has massive support in the USA and the UK, with many national organisations and NGOs already signatories even though it only started in January this year.
The link for the website of the campaign is: http://www.alltrials.net/
I noticed that MAPS is not a signatory even though the campaign covers the work of the organisation through it's pioneering work for the clinical use of psychoactive substances. I would highly recommend the organisation openly supports the campaign as MAPS already already follows the principles and it would help level the playing field for the thorough and honest work it does (in comparison to other statistic-fiddling manufacturers). If this campaign gets made law in enough countries, the current big league pharmaceutical companies may even help support the work of MAPS in psychedelic research as the results already speak for themselves, given that they will not be able to fall back on the usual tactics of shady patent strangle-holds based to maintain market share.
What do you think? I hope this of use to you. This is about ensuring patient safety, value for money and medical efficacy.
The link for the website of the campaign is: http://www.alltrials.net/
I noticed that MAPS is not a signatory even though the campaign covers the work of the organisation through it's pioneering work for the clinical use of psychoactive substances. I would highly recommend the organisation openly supports the campaign as MAPS already already follows the principles and it would help level the playing field for the thorough and honest work it does (in comparison to other statistic-fiddling manufacturers). If this campaign gets made law in enough countries, the current big league pharmaceutical companies may even help support the work of MAPS in psychedelic research as the results already speak for themselves, given that they will not be able to fall back on the usual tactics of shady patent strangle-holds based to maintain market share.
What do you think? I hope this of use to you. This is about ensuring patient safety, value for money and medical efficacy.